Compare BridgeBio Pharma Inc (BBIO) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs United Parcel Service Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while United Parcel Service Inc trades at $104.39 (market cap $89.09B). The key difference: United Parcel Service Inc is far larger — about 5.4× BridgeBio Pharma Inc's market cap, and United Parcel Service Inc pays a 6.26% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | UPS | |
|---|---|---|
Market Cap | $16.61B | $89.09B |
Sector | Health | Industrials |
52-Week High | $90.17 | $120.00 |
52-Week Low | $47.29 | $82.58 |
Enterprise Value | $18.16B | $113.11B |
Volume | — | 2,288,643 |
Dividend Yield | — | 6.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
UPS trades at $104.48, up 1.24% daily, with a bearish technical signal but recent earnings beats. Revenue declined to $88.66B in 2025, with net income margin at 5.08%, while valuation ratios like P/E of 19.42 and P/S of 0.99 suggest moderate pricing. The company maintains a strong dividend yield, with recent payouts of $1.64 per share, and analyst consensus is mixed amid cost-cutting efforts and Amazon volume reset.
Outlook is cautious due to margin pressures and competitive threats, but upside exists if operational efficiencies materialize. Risks include high debt-to-asset ratio of 33.02% and volatile cash flows. Analysts target $117.90 on average, implying potential growth, but investor sentiment remains divided given bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
